Download PDF
Pharmacopsychiatry 2013; 46(01): 39-40
DOI: 10.1055/s-0032-1321906
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Aseptic Gingivitis Related to Quetiapine Hemifumarate

M. Gahr
1   Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm, Germany
,
M. A. Kölle
1   Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm, Germany
,
R. W. Freudenmann
1   Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm, Germany
,
C. Schönfeldt-Lecuona
1   Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm, Germany
› Author Affiliations
Further Information

Publication History

received 18 May 2012
revised 08 July 2012

accepted 11 July 2012

Publication Date:
22 August 2012 (online)

Also available at
   Permissions and Reprints

Abstract

Quetiapine hemifumarate (QF) is widely used in psychiatry and is associated with regularly occurring side effects such as dizziness and metabolic problems. Apart from these typical adverse events the agent has attracted attention for several rare phenomena (priapism, cholestasis, rhabdomyolysis) that indeed feature anecdotal character, but are nevertheless indispensable for a comprehensive understanding of the factual risk profile of quetiapine. We present the first report of aseptic gingivitis associated with QF in a patient with mental retardation.

Key words

adverse events ·  - antipsychotic treatment  - · inflammation  - · second generation antipsychotics  - · side effects
 

  • References

  • 1 Wang Z, Kemp D, Chan P et al. Comparison of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14: 131-142
    CrossrefPubMedGoogle Scholar
  • 2 Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; CD000967
    PubMedGoogle Scholar
  • 3 Yargic I, Caferov C. Quetiapine dependence and withdrawal: a case report. Subst Abus 2011; 32: 168-169
    CrossrefPubMedGoogle Scholar
  • 4 Ceri M, Unverdi S, Altay M et al. Comment on: low-dose quetiapine-induced severe rhabdomyolysis. Ren Fail 2011; 33: 463-464
    CrossrefPubMedGoogle Scholar
  • 5 Tsai A. A case of recurrent priapism in the context of quetiapine use, discontinuation, and rechallenge. J Clin Psychopharmacol 2011; 31: 235-236
    CrossrefPubMedGoogle Scholar
  • 6 Klinke J, Shapira S, Akbari E et al. Quetiapine-associated cholestasis causing lipoprotein-X and pseudohyponatraemia. J Clin Pathol 2010; 63: 741-743
    CrossrefPubMedGoogle Scholar
  • 7 Poutanen O, Iso-Koivisto E, Työläjärvi M et al. Quetiapine-associated hypothyroidism in young female patients: a report of three cases. Pharmacopsychiatry 2010; 43: 237-239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Naranjo C, Busto U, Sellers E et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
    CrossrefPubMedGoogle Scholar
  • 9 Galas-Zgorzalewicz B, Borysewicz-Lewicka M, Zgorzalewicz M et al. The effect of chronic carbamazepine, valproic acid and phenytoin medication on the periodontal condition of epileptic children and adolescents. Funct Neurol 1996; 11: 187-193
    PubMedGoogle Scholar
  • 10 Seymour R, Thomason J, Ellis J. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996; 23: 165-175
    CrossrefPubMedGoogle Scholar